Disc Medicine, Inc., a clinical-stage biotechnology company, engages in discovering, developing, and commercializing novel treatments for patients suffering from serious hematologic diseases. It builds a portfolio of therapeutic candidates that address a spectrum of hematologic diseases by targeting fundamental biological pathways of red blood cell biology, primarily heme biosynthesis and iron homeostasis. Disc Medicine, Inc. is based in Watertown, Massachusetts.